全文获取类型
收费全文 | 3822篇 |
免费 | 188篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 88篇 |
妇产科学 | 73篇 |
基础医学 | 360篇 |
口腔科学 | 115篇 |
临床医学 | 289篇 |
内科学 | 929篇 |
皮肤病学 | 51篇 |
神经病学 | 440篇 |
特种医学 | 158篇 |
外科学 | 893篇 |
综合类 | 3篇 |
预防医学 | 103篇 |
眼科学 | 105篇 |
药学 | 142篇 |
中国医学 | 2篇 |
肿瘤学 | 267篇 |
出版年
2024年 | 6篇 |
2023年 | 40篇 |
2022年 | 108篇 |
2021年 | 192篇 |
2020年 | 105篇 |
2019年 | 121篇 |
2018年 | 149篇 |
2017年 | 98篇 |
2016年 | 129篇 |
2015年 | 144篇 |
2014年 | 185篇 |
2013年 | 245篇 |
2012年 | 307篇 |
2011年 | 314篇 |
2010年 | 184篇 |
2009年 | 172篇 |
2008年 | 201篇 |
2007年 | 213篇 |
2006年 | 197篇 |
2005年 | 155篇 |
2004年 | 166篇 |
2003年 | 138篇 |
2002年 | 149篇 |
2001年 | 36篇 |
2000年 | 20篇 |
1999年 | 27篇 |
1998年 | 24篇 |
1997年 | 20篇 |
1996年 | 10篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 13篇 |
1992年 | 11篇 |
1991年 | 14篇 |
1990年 | 14篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 16篇 |
1984年 | 8篇 |
1983年 | 7篇 |
1982年 | 8篇 |
1981年 | 8篇 |
1978年 | 4篇 |
1971年 | 4篇 |
1970年 | 3篇 |
1969年 | 9篇 |
1968年 | 5篇 |
1966年 | 5篇 |
排序方式: 共有4063条查询结果,搜索用时 0 毫秒
81.
82.
83.
84.
Alessandro Martorana Francesco Di Lorenzo Lorena Belli Giuseppe Sancesario Sofia Toniolo Fabrizio Sallustio Giulia Maria Sancesario Giacomo Koch 《CNS Neuroscience & Therapeutics》2015,21(12):921-925
Impaired amyloid beta (Aβ) metabolism is currently considered central to understand the pathophysiology of Alzheimer's disease (AD). Measurements of cerebrospinal fluid Aβ levels remain the most useful marker for diagnostic purposes and to individuate people at risk for AD. Despite recent advances criticized the direct role in neurodegeneration of cortical neurons, Aβ is considered responsible for synaptopathy and impairment of neurotransmission and therefore remains the major trigger of AD and future pharmacological treatment remain Aβ oriented. However, experimental and clinical findings showed that Aβ peptides could have a wider range of action responsible for cell dysfunction and for appearance of clinico‐pathological entities different from AD. Such findings may induce misunderstanding of the real role played by Aβ in AD and therefore strengthen criticism on its centrality and need for CSF measurements. Aim of this review is to discuss the role of CSF Aβ levels in light of experimental, clinical pathologic, and electrophysiological results in AD and other pathological entities to put in a correct frame the value of Aβ changes. 相似文献
85.
Elisa Maria Fiorelli Tiziana Carandini Delia Gagliardi Viviana Bozzano Mattia Bonzi Eleonora Tobaldini Giacomo Pietro Comi Elio Angelo Scarpini Nicola Montano Monica Solbiati 《Internal and emergency medicine》2018,13(8):1287-1303
The aim of our study is to compare patent foramen ovale (PFO) closure versus medical treatment and antiplatelet versus anticoagulant therapy in patients with cryptogenic stroke (CS) and PFO. We conducted a systematic review and meta-analysis with trial sequential analysis (TSA) of randomized trials. Primary outcomes are stroke or transient ischemic attack (TIA) and all-cause mortality. Secondary outcomes are peripheral embolism, bleeding, serious adverse events, myocardial infarction and atrial dysrhythmias. We performed an intention to treat meta-analysis with a random-effects model. We include six trials (3677 patients, mean age 47.3 years, 55.8% men). PFO closure is associated with a lower recurrence of stroke or TIA at a mean follow-up of 3.88 years compared to medical therapy [risk ratio (RR) 0.55, 95% CI 0.38–0.81; I2?=?40%]. The TSA confirms this result. No difference is found in mortality (RR 0.74, 95% CI 0.35–1.60; I2?=?0%), while PFO closure is associated with a higher incidence of atrial dysrhythmias (RR 4.55, 95% CI 2.16–9.60; I2?=?25%). The rate of the other outcomes is not different among the two groups. The comparison between anticoagulant and antiplatelet therapy shows no difference in terms of stroke recurrence, mortality and bleeding. There is conclusive evidence that PFO closure reduces the recurrence of stroke or TIA in patients younger than 60 years of age with CS. More data are warranted to assess the consequences of the increase in atrial dysrhythmias and the advantage of PFO closure over anticoagulants. 相似文献
86.
Vincenzo?Pavone Anna?MeleEmail author Daniela?Carlino Giorgina?Specchia Francesco?Gaudio Tommasina?Perrone Patrizio?Mazza Giulia?Palazzo Attilio?Guarini Giacomo?Loseto Prete?Eleonora Nicola?Cascavilla Potito?Scalzulli Angela?Melpignano Giovanni?Quintana Nicola?Di Renzo Giuseppe?Tarantini Silvana?Capalbo 《Annals of hematology》2018,97(10):1817-1824
Brentuximab vedotin (BV) shows a high overall response rate (ORR) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) after autologous transplant (ASCT). The aim of this multicenter study, conducted in nine Hematology Departments of Rete Ematologica Pugliese, was to retrospectively evaluate the efficacy and safety of BV as salvage therapy and as bridge regimen to ASCT or allogeneic transplant (alloSCT) in R/R HL patients. Seventy patients received BV. Forty-five patients (64%) were treated with BV as bridge to transplant:16 (23%) patients as bridge to ASCT and 29 (41%) as bridge to alloSCT. Twenty-five patients (36%), not eligible for transplant, received BV as salvage treatment. The ORR was 59% (CR 26%). The ORR in transplant naïve patients was 75% (CR 31%). In patients treated with BV as bridge to alloSCT, the ORR was 62% (CR 24%). In a multivariate analysis, the ORR was lower in refractory patients (p?<?0.005). The 2y-OS was 70%. The median PFS was 17 months. Ten of the 16 (63%) naïve-transplant patients received ASCT, with 50% in CR before ASCT. In the 29 patients treated with BV as bridge to alloSCT, 28 (97%) proceeded to alloSCT with 25% in CR prior to alloSCT. The most common adverse events were peripheral neuropathy (50%), neutropenia (29%) and anemia (12%). These data suggest that BV is well tolerated and very effective in R/R HL, producing a substantial level of CR. BV may also be a key therapeutic agent to achieve good disease control before transplant, improving post- transplant outcomes, also in refractory and heavily pretreated patients, without significant overlapping toxicities with prior therapies. 相似文献
87.
88.
89.
Marcello Rattazzi Elisabetta Faggin Elisa Bertacco Roberta Buso Massimo Puato Mario Plebani Martina Zaninotto Davide Condotta Giacomo Zoppellaro Leopoldo Pagliani Giuseppe Tarantini Sabino Iliceto Elisa Covolo Giuseppe Faggian Francesco Onorati Mikhail Dodonov Alessandro Daniotti Paola Pantano Zoran Olivari Giovanni Benfari Paolo Pauletto 《Journal of cardiovascular translational research》2018,11(4):329-338
We aimed to investigate whether the expression of the OPG/RANK/RANKL triad in peripheral blood mononuclear cells (PBMC) and circulating levels of markers of ectopic mineralization (OPG, FGF-23, PPi) are modified in patients with calcific aortic valve disease (CAVD). We found that patients affected by CAVD (n?=?50) had significantly higher circulating levels of OPG as compared to control individuals (p?=?0.003). No differences between the two groups were found in FGF-23 and PPi levels. RANKL expression was higher in the PBMC from CAVD patients (p?=?0.018) and was directly correlated with the amount of valve calcification (p?=?0.032). In vitro studies showed that treatment of valve interstitial cells (VIC) with RANKL plus phosphate was followed by increase in matrix mineralization (p?=?0.001). In conclusion, RANKL expression is increased in PBMC of patients with CAVD, is directly correlated with the degree of valve calcification, and promotes pro-calcific differentiation of VIC. 相似文献
90.
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 总被引:6,自引:1,他引:6
Giannelli F Moscarella S Giannini C Caini P Monti M Gragnani L Romanelli RG Solazzo V Laffi G La Villa G Gentilini P Zignego AL 《Blood》2003,102(4):1196-1201
Hepatitis C virus (HCV) may be associated with the mixed cryoglobulinemia syndrome and other B-cell lymphoproliferative disorders (LPDs). The t(14;18) translocation may play a pathogenetic role. Limited data are available regarding the effects of antiviral therapy on rearranged B-cell clones. We evaluated the effects of interferon and ribavirin on serum, B-lymphocyte HCV RNA, and t(14; 18) in 30 HCV+, t(14;18)+ patients without either mixed cryoglobulinemia syndrome or other LPDs. The t(14;18) translocation was analyzed by both bcl-2/JH polymerase chain reaction and bcl-2/JH junction sequencing in peripheral blood mononuclear cells in all patients. Fifteen untreated patients with comparable characteristics served as controls. Throughout the study, the presence or absence of both t(14;18) and HCV RNA sequences were, in most cases, associated in the same cell samples. At the end of treatment, t(14;18) was no longer detected in 15 patients (50%) with complete or partial virologic response, whereas it was persistently detected in nonresponders (P <.05), as well as in 14 of 15 control patients. In 4 responder patients, t(14;18) and HCV RNA sequences were no longer detected in blood cells after treatment, but were again detected after viral relapse; the same B-cell clones were involved in the pretreatment and posttreatment periods. In conclusion, this study suggests that antiviral therapy may induce regression of t(14;18)-bearing B-cell clones in HCV+ patients and that this phenomenon may be related, at least in part, to the antiviral effect of therapy. This in turn suggests that antiviral treatment may help prevent or treat HCV-related LPDs. 相似文献